ŠRÁMKOVÁ, Taťána, K. ŠRÁMKOVÁ, Jiří JARKOVSKÝ, Michal POHANKA a Aleš ČERMÁK. Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction. Biomedical Journal of Scientific & Technical Research. Westchester: Biomedical Research Network, roč. 26, č. 4, s. 20160-20166. ISSN 2574-1241. doi:10.26717/BJSTR.2020.26.004386. 2020.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction
Autoři ŠRÁMKOVÁ, Taťána (203 Česká republika, garant, domácí), K. ŠRÁMKOVÁ (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Michal POHANKA (203 Česká republika, domácí) a Aleš ČERMÁK (203 Česká republika, domácí).
Vydání Biomedical Journal of Scientific & Technical Research, Westchester, Biomedical Research Network, 2020, 2574-1241.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30217 Urology and nephrology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Kód RIV RIV/00216224:14110/20:00117461
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.26717/BJSTR.2020.26.004386
Klíčová slova anglicky Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 21. 12. 2020 06:54.
Anotace
Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.
VytisknoutZobrazeno: 23. 4. 2024 09:25